Section Arrow
IFRX.NASDAQ
- InflaRx NV
Quotes are at least 15-min delayed:2025/03/28 00:17 EDT
Last
 1.25
+0.01 (+0.81%)
Day High 
1.31 
Prev. Close
1.24 
1-M High
1.5 
Volume 
263.71K 
Bid
1.22
Ask
1.31
Day Low
1.2 
Open
1.24 
1-M Low
1.1319 
Market Cap 
83.25M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 1.26 
20-SMA 1.25 
50-SMA 1.86 
52-W High 2.815 
52-W Low 1.1319 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.78/-0.56
Enterprise Value
83.64M
Balance Sheet
Book Value Per Share
0.99
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
165.79K
Operating Revenue Per Share
0.00
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
OCEAOcean Biomedical0.078-0.0057-6.81%-- 
DRMADermata Therapeutics Inc.1.42+0.07+5.19%-- 
ONCOOnconetix Inc0.1077+0.0017+1.60%-- 
RGLSRegulus Therapeutics1.5+0.21+16.28%-- 
NKTXNkarta1.97+0.6+43.80%-- 
Quotes are at least 15-min delayed:2025/03/28 00:17 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.